Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.0%) at 17,140 as of Wednesday, Sept. 17, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,738 issues advancing vs. 1,242 declining with 174 unchanged. The Health Services industry currently sits up 0.3% versus the S&P 500, which is unchanged. A company within the industry that fell today was Smith & Nephew ( SNN), up 1.4%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Edwards Lifesciences ( EW) is one of the companies pushing the Health Services industry higher today. As of noon trading, Edwards Lifesciences is up $1.31 (1.3%) to $102.31 on light volume. Thus far, 270,057 shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 997,900 shares. The stock has ranged in price between $101.01-$102.32 after having opened the day at $101.10 as compared to the previous trading day's close of $101.00. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $10.8 billion and is part of the health care sector. Shares are up 53.6% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Edwards Lifesciences as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Edwards Lifesciences Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.